Company intelligence / Profile preview

Igyxos Biotherapeutics

Ownership: Private
Development stage: Preclinical

Overview

Igyxos initiated a Phase I clinical trial in November 2023 to evaluate the safety and tolerability of IGX12 in healthy volunteers, with results expected in 2025[5]. The company has completed a Single Ascending Dose study in both female and male volunteers that began in Q3 2023[9].

Therapeutic areas: Endocrinology
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

1 asset

igx12

Partnerships

Merck Biodevelopment/EMD MilliporeBaccinexERBCCRS (Berlin)[9]

Beyond the preview

Go deeper on Igyxos Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Igyxos Biotherapeutics.